Pharmacogenetics and oncology treatment for breast cancer.
about
Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions.A genome-wide association study of prognosis in breast cancer.Pharmacogenetics of antidepressant response.Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1Synthesis, structural characterization, and anticancer activity of a monobenzyltin compound against MCF-7 breast cancer cellsPharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer managementAntiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1-mediated metabolism.Identification of a potent herbal molecule for the treatment of breast cancer.The molecular genetics of breast cancer and targeted therapyABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.In vitro and in vivo assessments of two novel hydrazide compounds against breast cancer as well as mammary tumor cells.Effect of the microbial lipopeptide on tumor cell lines: apoptosis induced by disturbing the fatty acid composition of cell membraneCD243 gene polymorphism significantly associated with breast cancer susceptibility.Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.A New Protein Extract Inhibitor from Hypobranchial Purple Gland of Hexaplex trunculus, a Mediterranean Mollusk, Impairs the Motility of Human Glioblastoma U87 and the HeLa Cell Line of Cervical Carcinoma Cells.
P2860
Q33560299-8A742E31-B108-4C9D-B5FF-F1A088143115Q33780746-0165D440-AE92-481D-BE82-1F4F76BC4B13Q34155796-C2D43A27-2C87-4805-B59E-E6B09DC650CCQ35995530-65D31926-9D68-4EC8-BE3B-0E9C9E56DC08Q36332209-859E3059-5F72-4324-89B1-1C2BCD77727EQ36441485-42D85F3D-0AEB-46D7-81E5-DB8FFE0ECAB2Q36787314-54852F55-8E81-49D1-A177-0A661C9CDE4EQ37112358-48767EFC-0FDA-4F53-80B1-F54F433D6CE0Q37290512-E070D528-2EF3-47A9-A4F6-36D3082CA722Q37297173-259B74C0-36A7-4A6C-98E1-CFD25C34CA98Q38705755-4FFF34F4-FDF9-4060-A55A-C6630C3CAA19Q42566584-8F1C6222-2DC0-454F-B8FD-C36ECD591978Q43516060-8AF20B34-483F-4B7E-B3C0-2C415C678A46Q44360534-06C0268A-2CA6-4FF6-9B13-C028E870ADC7Q47588883-36055665-ECA6-482A-A163-71475983B9D7
P2860
Pharmacogenetics and oncology treatment for breast cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pharmacogenetics and oncology treatment for breast cancer.
@ast
Pharmacogenetics and oncology treatment for breast cancer.
@en
type
label
Pharmacogenetics and oncology treatment for breast cancer.
@ast
Pharmacogenetics and oncology treatment for breast cancer.
@en
prefLabel
Pharmacogenetics and oncology treatment for breast cancer.
@ast
Pharmacogenetics and oncology treatment for breast cancer.
@en
P2860
P356
P1476
Pharmacogenetics and oncology treatment for breast cancer.
@en
P2093
Howard L McLeod
Sharon Marsh
P2860
P304
P356
10.1517/14656566.8.2.119
P407
P577
2007-02-01T00:00:00Z